Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen TAVNEOS (avacopan by Year
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — U.S. product sales ($M) ($M)
Amgen TAVNEOS (avacopan: $423M in FY2025, up 65.2% from a year earlier.
Latest, FY2025
423
Period ended Dec 31, 2025
Change on a year earlier
+65.2%
256 in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| TAVNEOS — U.S. | 423 | 65 | % | 256 | * | 126”
Source: Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | TAVNEOS (avacopan — ANCA-Associated Vasculitis) — U.S. product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 423 | +65.2% | Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 256 | +103.2% | Form 10-K (amgn-20241231.htm, filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 126 | +687.5% | Form 10-K (amgn-20231231.htm, filed 2024-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 16 | – | Form 10-K (amgn-20221231.htm, filed 2023-02-09) ↗ |
Cite this data
StockData. (2026). Amgen TAVNEOS (avacopan ($M), annual FY2022–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-tavneos-us
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.